Pulmatrix (NASDAQ:PULM) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of pulmonary diseases. With a keen interest in leveraging its proprietary technology platform, Pulmatrix aims to improve the lives of patients suffering from serious pulmonary conditions including chronic obstructive pulmonary disease (COPD), asthma, and infectious diseases by developing inhaled therapies that lead to better efficacy, safety, and convenience. One of the company's flagship projects involves a novel formulation designed to effectively deliver medications directly to the lungs, promising a significant advancement in the treatment of pulmonary diseases. Pulmatrix is motivated by its mission to address the unmet medical needs within the respiratory health sector, pushing the boundaries of pulmonary medicine through cutting-edge research and development.